Erratum: Integration profile and safety of an adenovirus hybrid-vector utilizing hyperactive sleeping beauty transposase for somatic integration (PLoS ONE (2013) 8:10 (e75344) DOI: 10.1371/journal.pone.0075344);Integration Profile and Safety of an Adenovirus Hybrid-Vector Utilizing Hyperactive Sleeping Beauty Transposase for Somatic Integration

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zhang, Wenli ^a,b   Muck Hausl, Martin ^a   Wang, Jichang ^c   Sun, Chuanbo ^c   Gebbing, Maren ^d   Miskey, Csaba ^e   Ivics, Zoltan ^e   Izsvak, Zsuzsanna ^c   Ehrhardt, Anja ^a,f  

^a UNIVERSITY OF MUNICH   (Germany)

^b NORTHWEST A F UNIVERSITY   (China)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e PAUL EHRLICH INSTITUT   (Germany)

^f UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; FIREFLY LUCIFERASE; GENOMIC DNA; SLEEPING BEAUTY TRANSPOSASE; TRANSPOSASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CHROMOSOME; CONTROLLED STUDY; DNA INTEGRATION; DNA TRANSPOSITION; DRUG SAFETY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE VECTOR; GENOTOXICITY; HEMOPHILIA; HUMAN; HUMAN CELL; HYBRID; HYBRID VECTOR; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SOMATIC INTEGRATION; TRANSGENE; TRANSPOSON;

ADENOVIRIDAE; ANIMALIA; MUS;

ADENOVIRIDAE; ANIMALS; COMPUTATIONAL BIOLOGY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL; TRANSPOSASES;

EID: 84885032261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0228902     Document Type: Erratum

References (53)

1. Brunetti-Pierri N, Ng P, (2008) Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther 15: 553-560.
2. Jager L, Ehrhardt A, (2007) Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 7: 272-283.
3. Ehrhardt A, Kay MA, (2002) A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99: 3923-3930.
4. Jiang Z, Schiedner G, van Rooijen N, Liu CC, Kochanek S, et al. (2004) Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade. Mol Ther 10: 688-696.
5. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L, (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 98: 13282-13287.
6. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, et al. (2008) Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321: 1837-1841.
7. Toietta G, Koehler DR, Finegold MJ, Lee B, Hu J, et al. (2003) Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol Ther 7: 649-658.
8. Harui A, Suzuki S, Kochanek S, Mitani K, (1999) Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 73: 6141-6146.
9. Hillgenberg M, Tonnies H, Strauss M, (2001) Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J Virol 75: 9896-9908.
10. Stephen SL, Sivanandam VG, Kochanek S, (2008) Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med 10: 1176-1189.
11. Kubo S, Haga K, Tamamoto A, Palmer DJ, Ng P, et al. (2011) Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo. Mol Ther 19: 76-82.
12. Yant SR, Ehrhardt A, Mikkelsen JG, Meuse L, Pham T, et al. (2002) Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 20: 999-1005.
13. Ehrhardt A, Yant SR, Giering JC, Xu H, Engler JA, et al. (2007) Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol Ther 15: 146-156.
14. Soifer H, Higo C, Logg CR, Jih LJ, Shichinohe T, et al. (2002) A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol Ther 5: 599-608.
15. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F, (2004) Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 10: 660-670.
16. Wang H, Lieber A, (2006) A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette. J Virol 80: 11699-11709.
17. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z, (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91: 501-510.
18. Hausl M, Zhang W, Voigtlander R, Muther N, Rauschhuber C, et al. (2011) Development of adenovirus hybrid vectors for Sleeping Beauty transposition in large mammals. Curr Gene Ther 11: 363-374.
19. Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, et al. (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41: 753-761.
20. Yant SR, Huang Y, Akache B, Kay MA, (2007) Site-directed transposon integration in human cells. Nucleic Acids Res 35: e50.
21. Hausl MA, Zhang W, Muther N, Rauschhuber C, Franck HG, et al. (2010) Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther. 18: 1896-1906.
22. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, et al. (2000) Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 25: 35-41.
23. Jager L, Ehrhardt A, (2009) Persistence of high-capacity adenoviral vectors as replication-defective monomeric genomes in vitro and in murine liver. Hum Gene Ther 20: 883-896.
24. Palmer D, Ng P, (2003) Improved system for helper-dependent adenoviral vector production. Mol Ther 8: 846-852.
25. Jager L, Hausl MA, Rauschhuber C, Wolf NM, Kay MA, et al. (2009) A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc 4: 547-564.
26. Puntel M, Curtin JF, Zirger JM, Muhammad AK, Xiong W, et al. (2006) Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum Gene Ther 17: 531-544.
27. Yant SR, Wu X, Huang Y, Garrison B, Burgess SM, et al. (2005) High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 25: 2085-2094.
28. Staunstrup NH, Moldt B, Mates L, Villesen P, Jakobsen M, et al. (2009) Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 17: 1205-1214.
29. Vink CA, Gaspar HB, Gabriel R, Schmidt M, McIvor RS, et al. (2009) Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther 17: 1197-1204.
30. Moldt B, Miskey C, Staunstrup NH, Gogol-Doring A, Bak RO, et al. (2011) Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells. Mol Ther 19: 1499-1510.
31. Kato K, Yamashita R, Matoba R, Monden M, Noguchi S, et al. (2005) Cancer gene expression database (CGED): a database for gene expression profiling with accompanying clinical information of human cancer tissues. Nucleic Acids Res 33: D533-536.
32. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, et al. (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46.
33. Das RK, Hossain SU, Bhattacharya S, (2007) Protective effect of diphenylmethyl selenocyanate against CCl4-induced hepatic injury. J Appl Toxicol 27: 527-537.
34. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
35. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, et al. (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
36. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
37. Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, et al. (2010) Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 5: 1379-1395.
38. Aronovich EL, Bell JB, Khan SA, Belur LR, Gunther R, et al. (2009) Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 17: 1136-1144.
39. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, et al. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
40. Wu X, Li Y, Crise B, Burgess SM, (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
41. Nakai H, Wu X, Fuess S, Storm TA, Munroe D, et al. (2005) Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79: 3606-3614.
42. Schiedner G, Bloch W, Hertel S, Johnston M, Molojavyi A, et al. (2003) A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 14: 1631-1641.
43. Hartman ZC, Appledorn DM, Amalfitano A, (2008) Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132: 1-14.
44. Chuah MK, Collen D, VandenDriessche T, (2004) Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost. 30: 249-256.
45. Brunetti-Pierri N, Nichols TC, McCorquodale S, Merricks E, Palmer DJ, et al. (2005) Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther 16: 811-820.
46. Oka K, Pastore L, Kim IH, Merched A, Nomura S, et al. (2001) Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 103: 1274-1281.
47. Luo G, Ivics Z, Izsvak Z, Bradley A, (1998) Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci U S A 95: 10769-10773.
48. Yant SR, Kay MA, (2003) Nonhomologous-end-joining factors regulate DNA repair fidelity during Sleeping Beauty element transposition in mammalian cells. Mol Cell Biol 23: 8505-8518.
49. Yant SR, Park J, Huang Y, Mikkelsen JG, Kay MA, (2004) Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol 24: 9239-9247.
50. Galla M, Schambach A, Falk CS, Maetzig T, Kuehle J, et al. (2011) Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res 39: 7147-7160.
51. Huang X, Haley K, Wong M, Guo H, Lu C, et al. (2010) Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells. Hum Gene Ther 21: 1577-1590.
52. Bell JB, Aronovich EL, Schreifels JM, Beadnell TC, Hackett PB, (2010) Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery. Mol Ther 18: 1796-1802.
53. Grabundzija I, Irgang M, Mates L, Belay E, Matrai J, et al. (2010) Comparative analysis of transposable element vector systems in human cells. Mol Ther 18: 1200-1209.